Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation
Open Access
- 1 February 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 38 (2), 624-630
- https://doi.org/10.1161/01.str.0000250166.06949.95
Abstract
The efficacy of oral anticoagulation (OAC) for stroke prevention in patients with nonrheumatic atrial fibrillation (AF) has clearly been established. However, a substantial number of patients with AF who are at high risk for thromboembolic events are not candidates for long-term OAC. The left atrial appendix (LAA) is the most common place of thrombosis in patients with AF, and it can easily be excluded from the systemic circulation at the time of cardiac surgery by excision, ligation, suturing, or stapling. Currently, removal of the LAA at the time of mitral valve surgery is recommended to reduce future stroke risk. The ongoing LAA Occlusion Study (LAAOS) is evaluating the efficacy of the routine LAA occlusion in patients undergoing elective coronary artery bypass graft surgery. Recently, two devices specifically designed for percutaneous transcatheter LAA occlusion have been introduced: the Percutaneous LAA Transcatheter Occlusion (PLAATO; Appriva Medical Inc) and WATCHMAN LAA system (Atritech, Inc). More than 200 PLAATO devices were implanted worldwide in patients with nonrheumatic AF who were at high risk for ischemic stroke and not candidates for long-term OAC. In a follow-up time of 258 patient-years, an estimated 61% reduction in stroke risk was achieved with PLAATO procedure. The WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) study was designed to demonstrate the safety and efficacy of the WATCHMAN device in patients with nonvalvular AF who are eligible for long-term OAC. The trial is assessing whether the treatment arm (WATCHMAN device) is noninferior to the control arm (warfarin). Although present results suggest that LAA occlusion may reduce the long-term stroke risk, available data are still very limited. At present, percutaneous LAA occlusion may be an acceptable option in selected high-risk patients with AF who are not candidates for OAC. The current understanding of LAA exclusion for the prevention of stroke in patients with nonrheumatic AF is the major focus of this review.Keywords
This publication has 35 references indexed in Scilit:
- The Value of Estimated Functional Capacity in Estimating OutcomeJournal of the American College of Cardiology, 2006
- Left-atrial appendage occlusion with a new clip device: Preliminary Results in primatesInnovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2006
- Role of Diminished Renal Function in Cardiovascular MortalityJournal of the American College of Cardiology, 2005
- A novel device for left atrial appendage exclusionThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Surgical Closure of the Left Atrial Appendage – A Beneficial Procedure?JMIR AI, 2005
- Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for strokeAmerican Heart Journal, 2005
- Minimally Invasive Atrial Fibrillation Ablation Combined with a New Technique for Thoracoscopic Stapling of the Left Atrial Appendage: Case ReportThe Heart Surgery Forum, 2004
- Role of oral anticoagulation in management of atrial fibrillationHeart, 2004
- Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke preventionAmerican Heart Journal, 2003
- RESECTION OF THE AURICULAR APPENDAGESAnnals of Surgery, 1950